Present knowledge and recent developments in PM approach to COVID-19 disease prevention, evaluation, and management are pointed out. Better understanding of pathogenic pathways together with an accurate phenotype classification of patients presented with SARS-CoV-2 infection and symptoms might contribute to a more accurate definition of biomarkers and other diagnostic tools, which may lead to more precise mitigation strategies, personalized pharmacologic options, as well as new biological therapy developments.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- machine learning
- climate change
- high resolution
- air pollution
- deep learning
- prognostic factors
- particulate matter
- stem cells
- heavy metals
- polycyclic aromatic hydrocarbons
- cell therapy
- mass spectrometry